Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided warning content is strongly aligned with the FDA label excerpts for the boxed warning and Sections 5.1, 9.2, and related patient counseling, including risk assessment/education/monitoring and the stated increased risk with higher doses and unapproved administration methods (snorting/injection).
Category Scores
Accurate Statements
Focalin has high potential for abuse and misuse that can lead to substance use disorder/addiction.
Boxed Warning; Section 5.1
Misuse/abuse of Focalin can result in overdose and death.
Boxed Warning; Section 5.1; Section 9.2
Risk is increased with higher doses or unapproved methods of administration such as snorting or injection.
Boxed Warning; Section 5.1; Section 9.2
Focalin can be diverted for non-medical use into illicit channels/distribution.
Section 5.1; Section 9.2
Before prescribing, assess each patient’s risk for abuse/misuse/addiction.
Boxed Warning; Section 5.1
Educate patients and their families about abuse/misuse/addiction risks, proper storage, and proper disposal of unused drug.
Boxed Warning; Section 5.1; Section 17
Throughout treatment, reassess patient risk and frequently monitor for signs and symptoms of abuse/misuse/addiction.
Boxed Warning; Section 5.1
Unsupported Statements
Contradictions
Important Omissions
Specific overdose outcome descriptors (e.g., sympathomimetic cardiovascular/CNS effects such as tachyarrhythmias, seizures, hyperthermia, rhabdomyolysis) referenced via Overdosage (10).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
No contradictions to the provided boxed-warning/label excerpts were identified; core abuse/diversion/overdose-risk and risk assessment/education/monitoring elements are covered. The only gap is lack of detailed overdose outcome descriptors that are cross-referenced from Section 10.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Detailed overdose outcome examples from Section 10 were not explicitly included (cross-referenced in the boxed warning/5.1).
Suggested Improvement
If expanding the warning content, include or reference specific overdose consequences described in Overdosage (10) (e.g., severe cardiovascular/CNS effects and hyperthermia/rhabdomyolysis) while maintaining the existing core boxed-warning elements.